Opinion

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Photo from Lernik Ohanjanian/LinkedIn

Apr 30, 2024, 16:02

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Lernik Ohanjanian, Senior Medical Director at Miltenyi Biomedicine, shared on LinkedIn:

“We are standing on the cusp of revolution in drug discovery and development, with artificial intelligence (AI) emerging as a transformative tool to improve cancer patient outcomes.

Let’s use AI responsibly in target identification and validation, acceleration of clinical trials, personalization of treatments, enhancing drug formulations, streamlining regulatory approvals and above all improving patient outcomes.”

No alt text provided for this image

Source: Lernik Ohanjanian/LinkedIn

AI in healthcare AI in oncology cancer drug development drug discovery improving patient outcomes Lernik Ohanjanian Miltenyi Biomedicine OncoDaily Oncology

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity